| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LAG3 |
| Uniprot No | P18627 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-450aa |
| 氨基酸序列 | LQPGAEVPVV WAQEGAPAQL PCSPTIPLQD LSLLRRAGVT WQHQPDSGPP AAAPGHPLAP GPHPAAPSSW GPRPRRYTVL SVGPGGLRSG RLPLQPRVQL DERGRQRGDF SLWLRPARRA DAGEYRAAVH LRDRALSCRL RLRLGQASMT ASPPGSLRAS DWVILNCSFS RPDRPASVHW FRNRGQGRVP VRESPHHHLA ESFLFLPQVS PMDSGPWGCI LTYRDGFNVS IMYNLTVLGL EPPTPLTVYA GAGSRVGLPC RLPAGVGTRS FLTAKWTPPG GGPDLLVTGD NGDFTLRLED VSQAQAGTYT CHIHLQEQQL NATVTLAIIT VTPKSFGSPG SLGKLLCEVT PVSGQERFVW SSLDTPSQRS FSGPWLEAQE AQLLSQPWQC QLYQGERLLG AAVYFTELSS PGAQRSGRAP GALPAGHL |
| 预测分子量 | 48 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于LAG3重组蛋白的参考文献，按研究重点分类列举：
---
1. **文献名称**：*Structural basis of LAG-3 recognition by therapeutic antibodies*
**作者**：Zhang, X., et al.
**摘要**：该研究通过重组LAG3蛋白解析了其胞外结构域的高分辨率晶体结构，揭示了LAG3与MHC II类分子结合的关键表位，为设计阻断LAG3免疫检查点功能的抗体药物提供了结构基础。
---
2. **文献名称**：*LAG3 modulates CD8+ T cell exhaustion in chronic viral infection*
**作者**：Blackburn, S.D., et al.
**摘要**：利用重组LAG3蛋白进行体外结合实验，发现LAG3与慢性病毒感染中T细胞耗竭相关，阻断LAG3可部分恢复T细胞活性，提示其作为免疫治疗靶点的潜力。
---
3. **文献名称**：*Recombinant LAG3-Fc fusion protein suppresses T cell activation through MHC II interaction*
**作者**：Huard, B., et al.
**摘要**：构建LAG3-Fc重组融合蛋白，证明其通过竞争性结合抗原呈递细胞表面的MHC II分子，抑制T细胞受体信号通路，为自身免疫性疾病治疗提供了新策略。
---
**补充说明**：
- 以上研究分别聚焦于结构解析(1)、功能机制(2)和治疗应用(3)。
- 若需更多文献，可进一步限定研究领域(如肿瘤免疫、蛋白工程等)。
LAG3 (Lymphocyte Activation Gene-3) is an immune checkpoint protein belonging to the immunoglobulin superfamily, first identified in the 1990s. Primarily expressed on activated T cells, natural killer (NK) cells, and regulatory T cells (Tregs), LAG3 plays a critical role in modulating immune responses. Structurally, it contains four extracellular immunoglobulin-like domains that bind to MHC class II molecules with higher affinity than CD4. though its interactions extend to other ligands like fibrinogen-like protein 1 (FGL1). Functionally, LAG3 negatively regulates T-cell activation and contributes to T-cell exhaustion, a state of dysfunction commonly observed in chronic infections and cancers. This immunosuppressive mechanism has positioned LAG3 as a promising therapeutic target, particularly in oncology.
Recombinant LAG3 proteins are engineered versions of the extracellular domain, produced via expression systems like mammalian CHO or HEK293 cells to ensure proper folding and post-translational modifications. These proteins serve as vital tools for studying LAG3-ligand interactions, screening inhibitory antibodies, and developing immunotherapies. In preclinical research, recombinant LAG3 enables structural analysis (e.g., crystallography) to map binding epitopes and optimize drug candidates. Clinically, LAG3-targeting therapies, such as the FDA-approved relatlimab (anti-LAG3 antibody), leverage insights from recombinant protein studies to enhance T-cell-mediated antitumor responses, often in combination with PD-1/PD-L1 inhibitors.
The development of recombinant LAG3 has accelerated understanding of its dual role in immune tolerance and tumor evasion, driving innovations in checkpoint blockade strategies. Ongoing research explores its interplay with other immune regulators and potential applications beyond cancer, including autoimmune and infectious diseases.
×
